Advanced search
1 file | 1.42 MB Add to list

Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinoviruses

Author
Organization
Abstract
Background: Infections with human rhinoviruses (RVs) are responsible for millions of common cold episodes and the majority of asthma exacerbations, especially in childhood. No drugs specifically targeting RVs are available. Objective: We sought to identify specific anti-RV molecules based on DNAzyme technology as candidates to a clinical study. Methods: A total of 226 candidate DNAzymes were designed against 2 regions of RV RNA genome identified to be sufficiently highly conserved between virus strains (ie, the 59-untranslated region and cis-acting replication element) by using 3 test strains: RVA1, RVA16, and RVA29. All DNAzymes were screened for their cleavage efficiency against in vitro-expressed viral RNA. Those showing any catalytic activity were subjected to bioinformatic analysis of their reverse complementarity to 322 published RV genomic sequences. Further molecular optimization was conducted for the most promising candidates. Cytotoxic and off-target effects were excluded in HEK293 cell-based systems. Antiviral efficiency was analyzed in infected human bronchial BEAS-2B cells and ex vivo-cultured human sinonasal tissue. Results: Screening phase-generated DNAzymes characterized by either good catalytic activity or by high RV strain coverage but no single molecule represented a satisfactory combination of those 2 features. Modifications in length of the binding domains of 2 lead candidates, Dua-01(-L12R9) and Dua-02(-L10R11), improved their cleavage efficiency to an excellent level, with no loss in eminent strain coverage (about 98%). Both DNAzymes showed highly favorable cytotoxic/off-target profiles. Subsequent testing of Dua-01-L12R9 in BEAS-2B cells and sinonasal tissue demonstrated its significant antiviral efficiency. Conclusions: Effective and specific management of RV infections with Dua-01-L12R9 might be useful in preventing asthma exacerbations, which should be verified by clinical trials.
Keywords
Allergy, antisense, antiviral, asthma, atopy, DNAzyme, exacerbation, human rhinovirus, RNA, therapy, RESPIRATORY VIRAL-INFECTIONS, BRONCHIAL EPITHELIAL-CELLS, ASTHMA, SITE, DNA, EXACERBATIONS, PREVENTION, RESPONSES, VIRUSES, REPLICATION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.42 MB

Citation

Please use this url to cite or link to this publication:

MLA
Potaczek, Daniel P et al. “Development and Characterization of DNAzyme Candidates Demonstrating Significant Efficiency Against Human Rhinoviruses.” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 143.4 (2019): 1403–1415. Print.
APA
Potaczek, D. P., Unger, S. D., Zhang, N., Taka, S., Michel, S., Akdağ, N., Lan, F., et al. (2019). Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinoviruses. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 143(4), 1403–1415.
Chicago author-date
Potaczek, Daniel P, Sebastian D Unger, Nan Zhang, Styliani Taka, Sven Michel, Nesibe Akdağ, Feng Lan, et al. 2019. “Development and Characterization of DNAzyme Candidates Demonstrating Significant Efficiency Against Human Rhinoviruses.” Journal of Allergy and Clinical Immunology 143 (4): 1403–1415.
Chicago author-date (all authors)
Potaczek, Daniel P, Sebastian D Unger, Nan Zhang, Styliani Taka, Sven Michel, Nesibe Akdağ, Feng Lan, Markus Helfer, Christoph Hudemann, Markus Eickmann, Chrysanthi Skevaki, Spyridon Megremis, Anne Sadewasser, Bilal Alashkar Alhamwe, Fahd Alhamdan, Mübeccel Akdis, Michael R Edwards, Sebastian L Johnston, Cezmi A Akdis, Stephan Becker, Claus Bachert, Nikolaos G Papadopoulos, Holger Garn, and Harald Renz. 2019. “Development and Characterization of DNAzyme Candidates Demonstrating Significant Efficiency Against Human Rhinoviruses.” Journal of Allergy and Clinical Immunology 143 (4): 1403–1415.
Vancouver
1.
Potaczek DP, Unger SD, Zhang N, Taka S, Michel S, Akdağ N, et al. Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinoviruses. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2019;143(4):1403–15.
IEEE
[1]
D. P. Potaczek et al., “Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinoviruses,” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 143, no. 4, pp. 1403–1415, 2019.
@article{8582239,
  abstract     = {Background: Infections with human rhinoviruses (RVs) are responsible for millions of common cold episodes and the majority of asthma exacerbations, especially in childhood. No drugs specifically targeting RVs are available. 
Objective: We sought to identify specific anti-RV molecules based on DNAzyme technology as candidates to a clinical study. 
Methods: A total of 226 candidate DNAzymes were designed against 2 regions of RV RNA genome identified to be sufficiently highly conserved between virus strains (ie, the 59-untranslated region and cis-acting replication element) by using 3 test strains: RVA1, RVA16, and RVA29. All DNAzymes were screened for their cleavage efficiency against in vitro-expressed viral RNA. Those showing any catalytic activity were subjected to bioinformatic analysis of their reverse complementarity to 322 published RV genomic sequences. Further molecular optimization was conducted for the most promising candidates. Cytotoxic and off-target effects were excluded in HEK293 cell-based systems. Antiviral efficiency was analyzed in infected human bronchial BEAS-2B cells and ex vivo-cultured human sinonasal tissue. 
Results: Screening phase-generated DNAzymes characterized by either good catalytic activity or by high RV strain coverage but no single molecule represented a satisfactory combination of those 2 features. Modifications in length of the binding domains of 2 lead candidates, Dua-01(-L12R9) and Dua-02(-L10R11), improved their cleavage efficiency to an excellent level, with no loss in eminent strain coverage (about 98%). Both DNAzymes showed highly favorable cytotoxic/off-target profiles. Subsequent testing of Dua-01-L12R9 in BEAS-2B cells and sinonasal tissue demonstrated its significant antiviral efficiency. 
Conclusions: Effective and specific management of RV infections with Dua-01-L12R9 might be useful in preventing asthma exacerbations, which should be verified by clinical trials.},
  author       = {Potaczek, Daniel P and Unger, Sebastian D and Zhang, Nan and Taka, Styliani and Michel, Sven and Akdağ, Nesibe and Lan, Feng and Helfer, Markus and Hudemann, Christoph and Eickmann, Markus and Skevaki, Chrysanthi and Megremis, Spyridon and Sadewasser, Anne and Alashkar Alhamwe, Bilal and Alhamdan, Fahd and Akdis, Mübeccel and Edwards, Michael R and Johnston, Sebastian L and Akdis, Cezmi A and Becker, Stephan and Bachert, Claus and Papadopoulos, Nikolaos G and Garn, Holger and Renz, Harald},
  issn         = {0091-6749},
  journal      = {JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY},
  keywords     = {Allergy,antisense,antiviral,asthma,atopy,DNAzyme,exacerbation,human rhinovirus,RNA,therapy,RESPIRATORY VIRAL-INFECTIONS,BRONCHIAL EPITHELIAL-CELLS,ASTHMA,SITE,DNA,EXACERBATIONS,PREVENTION,RESPONSES,VIRUSES,REPLICATION},
  language     = {eng},
  number       = {4},
  pages        = {1403--1415},
  title        = {Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinoviruses},
  url          = {http://dx.doi.org/10.1016/j.jaci.2018.07.026},
  volume       = {143},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: